NICE reverses decision on medication for relapsing multiple sclerosis

The current topic of discussion regarding NICE is how its recent changes will impact patient access to medicine but, away from the headlines, the body continues to perform its role of determining which medicines will be available to patients. In this case, it has approved Biogen’s Zinbryta for patients suffering from relapsing remitting multiple sclerosis, though with the caveat of there being particular circumstances dependent for its use.
read more